



Veryan announces completion of enrolment in the Mimics study

March 2012 – Vascular disease specialist Veryan has announced that the final subject has been enrolled in the randomised phase of the Mimics study. The enrolment took place at Herz Zentrum, Bad Krozingen, Germany, where the Mimics study's Principal Investigator, Professor Thomas Zeller is based.

The MIMICS study is a multicentre clinical evaluation of the safety and performance of the BioMimics 3D stent and delivery system in subjects with peripheral artery disease undergoing femoropopliteal artery intervention. It was initiated in Bad Krozingen, Germany in February 2010 with the initial First in Human (FIH) cohort of 10 subjects. This cohort provided clinical safety evidence at 30 days to support commencement of the randomised part of the study. In the randomised phase, subjects were randomised in a 2:1 ratio to receive either the BioMimics 3D stent or a straight Nitinol comparator stent. Total enrolment in the study was 50 BioMimics 3D stents (10 in the FIH and 50 in the randomised Phase) and 26 controls. The subjects will continue to be clinically followed to 24 months post stent implant.

A CE Mark submission is scheduled for the summer of 2012.

About Veryan

Veryan is developing innovative solutions to improve the performance of vascular stents using the principles of biomimicry. Veryan's BioMimics 3D™ stent technology involves adapting traditional straight stent designs to a three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. BioMimics 3D technology is designed to improve clinical performance by improving flow conditions in, and bio-mechanical performance of, stented vessels.

Pre-clinical studies have shown that BioMimics 3D stent technology may significantly reduce restenosis (the narrowing of stented arterial segments) and confer significant mechanical benefits: the BioMimics 3D stent is more flexible, kink and fracture resistant than conventional counterparts.

For further information, please visit: www.veryanmed.com

-Ends-

Media contact:

Richard Kenyon
richard@rkpr.co.uk
+44 7831 569940